A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: Excess mortality associated with high-dose clarithromycin

Clinical Infectious Diseases

Volumn 29, Issue 1, 1999, Pages 125-133

  Cohn, David L ^{a,b,c,d,e,f,g,h,i,j,k,m}   Fisher, Evelyn J ^{a,b,c,d,e,f,g,h,i,j,k}   Peng, Grace T ^{a,b,c,d,e,f,g,h,i,j,k}   Hodges, James S ^{a,b,c,d,e,f,g,h,i,j,k}   Chesnut, Jill ^{a,b,c,d,e,f,g,h,i,j,k}   Child, Carroll C ^{a,b,c,d,e,f,g,h,i,j,k}   Franchino, Barbara ^{a,b,c,d,e,f,g,h,i,j,k}   Gibert, Cynthia L ^{a,b,c,d,e,f,g,h,i,j,k}   El Sadr, Wafaa ^{a,b,c,d,e,f,g,h,i,j,k}   Hafner, Richard ^{a,b,c,d,e,f,g,h,i,j,k}   Korvick, Joyce ^{a,b,c,d,e,f,g,h,i,j,k,l}   Ropka, Mary ^{a,b,c,d,e,f,g,h,i,j,k}   Heifets, Leonid ^{a,b,c,d,e,f,g,h,i,j,k}   Clotfelter, Jan ^{a,b,c,d,e,f,g,h,i,j,k}   Munroe, David ^{a,b,c,d,e,f,g,h,i,j,k}   Horsburgh Jr , C Robert ^{a,b,c,d,e,f,g,h,i,j,k}  

^a Denver Community Programs for Clinical Research on AIDS   (United States)

^b Richmond AIDS Consortium   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Washington Regional AIDS Program   (United States)

^g HARLEM HOSPITAL CENTER   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^j Louisiana Comm AIDS Res Program   (United States)

^k EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^m DENVER PUBLIC HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CLARITHROMYCIN; CLOFAZIMINE; ETHAMBUTOL; FLUCONAZOLE; RIFABUTIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; FEMALE; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UVEITIS;

EID: 0032794286     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/520141     Document Type: Article

References (45)

1. 1. Horsburgh CR Jr. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med 1991;324:1332-8.
2. 2. Ellner JJ, Goldberger MJ, Parenti DM. Mycobacterium avium infection and AIDS: a therapeutic dilemma in rapid evolution. J Infect Dis 1991;163:1326-35.
3. 3. Nightingale SD, Byrd LT, Southern PM, Jockusch JD, Cal SX, Wynne BA. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus positive patients. J Infect Dis 1992;165:1082-5.
4. 4. Gordin FM, Cohn DL, Sullam PM, Schoenfelder JR, Wynne BA, Horsburgh CR. Early manifestations of disseminated Mycobacterium avium complex disease: a prospective evaluation. J Infect Dis 1997;176:126-32.
5. 5. Hawkins CC, Gold JWM, Whimbey E, et al. Mycobaterium avium complex infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1986;105:184-8.
6. 6. Horsburgh C, Havlik J, Ellis D, et al. Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy. Am Rev Respir Dis 1991;144:557-9.
7. 7. Chin DP, Reingold AL, Stone EN, et al. The impact of Mycobacterium avium complex bacteremia and its treatment on survival of AIDS patients - a prospective study. J Infect Dis 1994;170:578-84.
8. 8. Naik S, Ruck R. In-vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. J Antimicrob Chemother 1989;33:1614-6.
9. 9. Heifets LB, Lindholm-Levy PJ, Comstock RD. Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium. Am Rev Respir Dis 1992;145:856-8.
10. 10. Dautzenberg B, Truffot C, Legris S, et al. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome: a controlled clinical trial. Am Rev Respir Dis 1991;144:564-9.
11. 11. Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: a randomized, double-blind, dose-ranging study in patients with AIDS. Ann Intern Med 1994;121:905-11.
12. 12. Gupta S, Blahunka K, Dellerson M, Craft JC, Smith T. Interim results of safety and efficacy of clarithromycin in the treatment of disseminated Mycobacterium avium complex infection in patients with AIDS [abstract no 892]. In: Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy (Anaheim, California). Washington, DC: American Society for Microbiology, 1992:259.
13. 13. Shafran SD, Singer J, Zarowny DP, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. N Engl J Med 1996;335:377-83.
14. 14. Burman WJ, Reves RR, Rietmeijer CA, Cohn DL. A retrospective comparison of clarithromycin versus rifampin in combination treatment for Mycobacterium avium complex disease in AIDS: clarithromycin decreases transfusion requirements. Int J Tuberc Lung Dis 1997;2:163-9.
15. 15. Ives DV, Davis RB, Currier JS. Impact of clarithromycin and azithromycin on patterns of treatment and survival among AIDS patients with disseminated Mycobacterium avium complex. AIDS 1995;9:261-6.
16. 16. Kemper CA, Meng TC, Nussbaum J, et al. Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen: rifampin, ethambutol, clofazimine, and ciprofloxacin. Ann Intern Med 1992;116:466-72.
17. 17. Chiu J, Nussbaum J, Bozzette S, et al. Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. Ann Intern Med 1990;113:358-61.
18. 18. Center for Drug Evaluation and Research. Summary results, antiviral drug advisory committee meeting. Washington, DC: US Food and Drug Administration, 1993:1-6.
19. 19. Goldberger M, Masur H. Clarithromycin therapy for Mycobacterium avium complex disease in patients with AIDS: potential and problems (editorial). Ann Intern Med 1994;121:974-5.
20. 20. Masur H, US Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with human immunodeficiency virus. N Engl J Med 1993;329:898-904.
21. 21. Kemper CA, Havlir D, Haghighat D, et al. The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex bacteremia in patients with AIDS. J Infect Dis 1994;170:157-64.
22. 22. Yajko DM, Kirihara J, Sanders C, Nassos P, Hadley WK. Antimicrobial synergism against Mycobacterium avium complex strains isolated from patients with acquired immune deficiency syndrome. Antimicrob Agents Chemother 1988;32:1392-5.
23. 23. Sullam PM, Gordin FM, Wynne BA, Group RT. Efficacy of rifabutin in the treatment of disseminated infection due to Mycobacterium avium complex. Clin Infect Dis 1994;19:84-6.
24. 24. Hoy J, Mijch A, Sandland M, Grayson L, Lucas R, Dwyer B. Quadruple-drug therapy for Mycobacterium avium intracellulare bacteremia in AIDS patients. J Infect Dis 1990;161:801-5.
25. 25. Siddiqi SH, Heifets LB, Cynamon MH, et al. Rapid broth macrodilution method for determination of MICs for Mycobacterium avium isolates. J Clin Microbiol 1993;31:2332-8.
26. 26. Heifets LB. Susceptibility testing of Mycobacterium avium complex isolates. Antimicrob Agents Chemother 1996;40:1759-67.
27. 27. Sanchez T, Vanderkolk J, Seay S, Heifets L. Quantitation of mycobacteria in blood specimens from patients with AIDS. Tuberc Lung Dis 1994;75:386-90.
28. 28. Lawless JF. Statistical models and methods for lifetime data. New York: John Wiley & Sons, 1982.
29. 29. Cox DR, Hinkley DV. Theoretical statistics. London: Chapman and Hall, 1974.
30. 30. Morikawa K, Oseko F, Morikawa S, Iwamoto K. Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in-vitro. Antimicrob Agents Chemother 1994;38:2643-7.
31. 31. Morikawa K, Watabe H, Araake M, Morikawa S. Modulatory effect of antibiotics on cytokine production by human monocytes in-vitro. Antimicrob Agents Chemother 1996;40:1366-70.
32. 32. Hafner R, Bethel J, Power M, et al. Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. Antimicrob Agents Chemother 1998;42:631-9.
33. 33. Dube MP, Sattler FR, Torriani FJ, et al. A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy. J Infect Dis 1997;176:1225-32.
34. 34. May T, Brel F, Beuscart C, et al. Comparison of combination therapy regimens for treatment of human immunodeficiency virus infected patients with disseminated bacteremia due to Mycobacterium avium. Clin Infect Dis 1997;25:621-9.
35. 35. Chaisson RE, Keiser P, Pierce M, et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS 1997;11:311-7.
36. 36. De Cian W, Sassella D, Wynne B. Clinical experience with rifabutin in the treatment of mycobacterial infections. Scand J Infect Dis Suppl 1995;98:22-6.
37. 37. Gordin FM, Sullam PM, Shafran SD, et al. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. Clin Infect Dis 1999;28:1080-5.
38. 38. Morse EV, Simon PM, Coburn M, Hyslop N, Greenspan D, Balsom PM. Determinants of subject compliance within an experimental anti-HIV drug protocol. Soc Sci Med 1991;32:1161-7.
39. 39. Coffin J. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995;267:483-9.
40. 40. Trapnell CB, Narang PK, Li R, Lavelle JP. Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. Ann Intern Med 1996;124:573-6.
41. 41. Shafran SD, Singer J, Zarowny DP, et al. Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for Mycobacterium avium complex bacteremia: a multivariate analysis. J Infect Dis 1998;177:252-5.
42. 42. Benson CA, Cohn DL, Williams P, ACTG 196/CPCRA 009 Protocol Team. A phase III prospective, randomized, double-blind study of the safety and efficacy of clarithromycin (CLA) vs. rifabutin (RBT) vs. CLA+RBT for prevention of Mycobacterium avium complex disease in HIV-positive patients with CD4 counts <100 cells/μl. [abstract no 205]. In: Third Conference on Retroviruses and Opportunistic Infections (Washington, DC). Alexandria, VA: Infectious Diseases Society of America, 1996:91.
43. 43. Jacobsen MA, Besch CL, Child C, et al. Primary prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with advanced human immunodeficiency virus disease: results of a randomized trial. J Infect Dis 1994;169:384-94.
44. 44. Salmon-Ceron D, Fontbonne A, Saba J, et al. Lower survival in AIDS patients receiving dapsone compared with acrosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia. J Infect Dis 1995;172:656-64.
45. 45. National Institute of Allergy and Infectious Diseases. A note to physicians: important therapeutic information on the dosing of clarithromycin for the treatment of disseminated Mycobacterium avium complex (DMAC) infection in HIV-infected patients. Bethesda, MD: National Institutes of Health, 1996.